<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="3395">
  <stage>Registered</stage>
  <submitdate>13/12/2011</submitdate>
  <approvaldate>13/12/2011</approvaldate>
  <nctid>NCT01492426</nctid>
  <trial_identification>
    <studytitle>Study Comparing Daclatasvir (BMS-790052) With Telaprevir Combined With Peginterferon Alfa-2a and Ribavirin in Patients With Chronic Hepatitis C Virus Infection</studytitle>
    <scientifictitle>A Phase 3 Evaluation of BMS-790052 (Daclatasvir) Compared With Telaprevir in Combination With Peginterferon Alfa-2a and Ribavirin in Treatment-Naive Patients With Chronic Hepatitis C</scientifictitle>
    <utrn />
    <trialacronym>COMMAND-3</trialacronym>
    <secondaryid>2011-004237-14</secondaryid>
    <secondaryid>AI444-052</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Hepatitis C</healthcondition>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Other infectious diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Oral and Gastrointestinal</conditioncode1>
      <conditioncode2>Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Daclatasvir
Treatment: drugs - Telaprevir
Treatment: drugs - Peginterferon alfa-2a
Treatment: drugs - Ribavirin

Experimental: Daclatasvir + Peginterferon alfa-2a + Ribavirin - 

Experimental: Telaprevir + Peginterferon alfa-2a + Ribavirin - 


Treatment: drugs: Daclatasvir
Film-coated tablet, oral, 60 mg, once daily, 24 weeks

Treatment: drugs: Telaprevir
Film-coated tablet, oral, 750 mg, 3 times daily

Treatment: drugs: Peginterferon alfa-2a
Solution for injection, subcutaneous injection, 180 µg, weekly

Treatment: drugs: Ribavirin
Film-coated tablet, oral, in a body weight stratified dose range of 1000-1200 mg per day

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Percentage of Genotype 1b Participants With Sustained Virologic Response at Follow-up Week 12 (SVR12) - SVR12 was defined as hepatitis C virus RNA levels to be lower than the limit of quantitation, ie, 25 IU/mL target detected or target not detected at follow-up Week 12.</outcome>
      <timepoint>Week 12 (Follow-up period)</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of Genotype 1b Participants With Rapid Virologic Response (RVR) at Week 4 - RVR was defined as hepatitis c virus RNA levels lower than lower limit of quantitation, ie, 25 IU/mL target not detected at Week 4 of treatment.</outcome>
      <timepoint>Week 4</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of Genotype 1b Participants With Extended Rapid Virologic Response (eRVR) at Both Week 4 and Week 12 - eRVR was defined as hepatitis C virus RNA levels lower than the lower limit of quantitation, ie, 25 IU/mL target not detected at both Weeks 4 and 12 of treatment.</outcome>
      <timepoint>Week 4, Week 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of Genotype 1b Participants With Complete Early Virologic Response (cEVR) - cEVR was defined as hepatitis C virus RNA levels lower than the lower limit of quantitation, ie, 25 IU/mL target not detected at Week 12 of treatment.</outcome>
      <timepoint>Week 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of Genotype 1b Participants With Sustained Virologic Response at Follow-up Week 24 (SVR24) - SVR24 was defined as hepatitis C virus RNA levels lower than the lower limit of quantitation, ie, 25 IU/mL target detected or target not detected at follow-up week 24 of treatment.</outcome>
      <timepoint>Week 24 (Follow-up period)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of Genotype 1a Participants With Sustained Virologic Response at Follow-up Week 12 (SVR12) - SVR12 was defined as hepatitis C virus RNA levels lower than the lower limit of quantitation, ie, 25 IU/mL target detected or target not detected at follow-up week 12 of treatment.</outcome>
      <timepoint>Week 12 (Follow-up period)</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Key 

          -  Participants chronically infected with hepatitis C virus (HCV) genotype 1a or 1b

          -  HCV RNA viral load =10,000 IU/mL

          -  No prior treatment including but not limited to interferon, ribavirin, and
             direct-acting antivirals

          -  No history of cirrhosis liver biopsy within 3 years or Fibroscan® within 1 year

          -  Body mass index of 18 to 35 kg/m^2

          -  Negative for HIV and hepatitis B virus

        Key</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Evidence of decompensated liver disease

          -  Evidence of medical condition other than HCV contributing to chronic liver disease</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/01/2012</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>605</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/03/2014</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,QLD,SA,VIC</recruitmentstate>
    <hospital>Local Institution - Camperdown</hospital>
    <hospital>Local Institution - Penrith</hospital>
    <hospital>Local Institution - Westmead Nsw</hospital>
    <hospital>Local Institution - Greenslopes Qld</hospital>
    <hospital>Local Institution - Adelaide</hospital>
    <hospital>Local Institution - Fitzroy</hospital>
    <hospital>Local Institution - Prahran</hospital>
    <postcode>2050 - Camperdown</postcode>
    <postcode>2750 - Penrith</postcode>
    <postcode>2145 - Westmead Nsw</postcode>
    <postcode>4120 - Greenslopes Qld</postcode>
    <postcode>5000 - Adelaide</postcode>
    <postcode>3065 VIC - Fitzroy</postcode>
    <postcode>3181 - Prahran</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Alabama</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Arizona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Connecticut</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Georgia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Illinois</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Maryland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Minnesota</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Missouri</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Rhode Island</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Argentina</country>
      <state>Buenos Aires</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Argentina</country>
      <state>Santa Fe</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Austria</country>
      <state>Linz</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Austria</country>
      <state>Wien</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>Sao Paulo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Alberta</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>British Columbia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Manitoba</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Denmark</country>
      <state>Hvidovre</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Denmark</country>
      <state>Odense</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Besancon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Bondy Cedex</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Grenoble Cedex 09</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Lille Cedex</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Paris Cedex 12</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Paris Cedex 13</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Pessac</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Strasbourg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Berlin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Essen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Frankfurt</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Freiburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Hamburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Hannover</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Koeln</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Haifa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Nazareth</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Tel Aviv</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Zefat</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Bergamo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Cisanello (pisa)</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Firenze</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Napoli</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Torino</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Bialystok</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Chorzow</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Kielce</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Myslowice</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Raciborz</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Wroclaw</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Moscow</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Alcorcon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Barcelona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Valencia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Switzerland</country>
      <state>Zurich</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Greater London</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Scotland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>West Midlands</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Bristol-Myers Squibb</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to compare the effectiveness of BMS-790052 (Daclatasvir) and
      Telaprevir when given in combination with Peginterferon alfa-2a and Ribavirin in genotype 1b
      patients</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01492426</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Bristol-Myers Squibb</name>
      <address>Bristol-Myers Squibb</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>